No-Reflow Phenomenon Clinical Trial
Official title:
Mean Platelet Volume and STEMI Clinical Risk Scores in Prediction of Impaired Myocardial Perfusion In Acute STEMI Patients Undergoing PPCI.
Verified date | May 2024 |
Source | Assiut University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Predicting no reflow in ppci of STEMI patients using mean platelet volume together with STEMI clinical risk scores
Status | Completed |
Enrollment | 640 |
Est. completion date | May 1, 2024 |
Est. primary completion date | February 28, 2021 |
Accepts healthy volunteers | |
Gender | All |
Age group | 16 Years and older |
Eligibility | Inclusion Criteria: - patients presenting with acute STEMI, within 24 hours of symptoms, fulfilling criteria for PPCI protocol in our facility Exclusion Criteria: - patients presenting more than 24 hours of symptoms onset - patients not eligible for PPCI program in our facility |
Country | Name | City | State |
---|---|---|---|
Egypt | Assiut university hospital | Assiut |
Lead Sponsor | Collaborator |
---|---|
Assiut University |
Egypt,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of participents with No reflow after PPCI and in hospital mortality | No reflow: suboptimal myocardial reperfusion through a part of coronary circulation without angiographic evidence of mechanical vessel obstruction.
In hospital mortality |
Within 48 hours from admission |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT03264859 -
NGAL and Its Association With the No-reflow Phenomenon in ST-elevation Myocardial Infarction
|
N/A | |
Not yet recruiting |
NCT06342141 -
Empagliflozin for No-reflow Phenomenon in PCI for STEMI
|
Phase 2 | |
Not yet recruiting |
NCT04835974 -
the No-reflow in Diabetic Patients Treated With Primary Percutaneous Coronary Intervention (PCI)
|
N/A | |
Not yet recruiting |
NCT05360602 -
Alpha Lipoic Acid Effect on No-Reflow Phenomenon
|
N/A | |
Completed |
NCT02054000 -
Intracoronary Tirofiban on No-Reflow Phenomena
|
Phase 4 | |
Not yet recruiting |
NCT05393557 -
Upfront Premedication For Reduction of Microvascular Obstruction and No-reflow in Treating ST-segment Elevation Myocardial Infarction
|
N/A | |
Completed |
NCT04699110 -
Adrenaline for the Treatment of No-Reflow in Normotensive Patients
|
Phase 4 | |
Completed |
NCT04573751 -
The EPIVER Randomized Controlled Trial
|
N/A | |
Not yet recruiting |
NCT02233790 -
Ticagrelor and Clopidogrel on Reperfusion in Patients With AMI
|
Phase 4 | |
Recruiting |
NCT05427786 -
A Study to Evaluate the Impact of Pre-procedural Intracoronary Nicorandil Injection to PREVENT reductioN Of decREased TIMI FLOW in Patients Who Undergoing Percutaneous Coronary Intervention for the Coronary Artery Disease
|
Phase 4 | |
Completed |
NCT05355532 -
Genetic Determinants of the Coronary Microvascular Obstruction in PCI
|